Medtide Inc is a China-based company mainly engaged in the contract research, development and manufacturing of peptide. The Company mainly provides contract research organization (CRO) services, namely peptide new chemical entity (NCE) discovery synthesis, contract development and manufacturing organization (CDMO) services, namely peptide chemistry, manufacturing, and control (CMC) development and commercial manufacturing. The Company's services primarily focus on providing customers with active pharmaceutical ingredients (APIs) rather than drug products. The Company also provides customers with peptide drug development, production, and CMC filing support services. The Company mainly operates its business in the domestic market and overseas markets.

Employees

596

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
04/26/04	HK$19.23	-1.23%	1,44,100
03/26/03	HK$19.47	+0.52%	2,10,100
02/26/02	HK$19.37	+1.41%	2,95,000
30/26/30	HK$19.10	-1.60%	1,26,700
29/26/29	HK$19.41	-3.05%	88,400

Delayed Quote Hong Kong S.E.

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

16.56CNY

Average target price

19.66CNY

Spread / Average Target

+18.76%

Consensus

Net sales - Rate of surprise

Rate of surprise - Net sales - Annual - Medtide Inc.

Company calendar

Delayed Hong Kong S.E. 09:22:50 04/11/2026 am IST			5-day change	1st Jan Change
19.23 ^HKD	-1.23%		-3.95%	-36.91%

24/09	Medtide Acquires China Land, Property for Peptide CDMO Project	MT
24/09	Medtide Inc. Announces Resignation of Li Lingmei as Executive Director, Effective September 24, 2026	CI

Market Cap	234.81Cr 276.08Cr 35Cr 31Cr 29Cr 26Cr 49Cr 3.33TCr 50Cr 344.67Cr 138.65Cr 1.76TCr 132.07Cr 129.25Cr 5.58TCr	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	176.91Cr 208.01Cr 27Cr 24Cr 22Cr 20Cr 37Cr 2.51TCr 38Cr 259.69Cr 104.47Cr 1.33TCr 100Cr 97Cr 4.2TCr	EV / Sales 2026 *	2.96x	EV / Sales 2027 *	2.29x
Free-Float	19.48%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Hong Kong S.E.	3880	Delayed
Deutsche Boerse AG	FQ2	Delayed

24/09	Medtide Acquires China Land, Property for Peptide CDMO Project	MT
24/09	Medtide Inc. Announces Resignation of Li Lingmei as Executive Director, Effective September 24, 2026	CI
21/09	Medtide Inc.(SEHK:3880) added to S&P Global BMI Index	CI
27/08	Medtide Inc. Reports Earnings Results for the Half Year Ended June 30, 2026	CI
31/07	Medtide Names CFO	MT
31/07	Medtide Inc. Announces Appointment of Ding Lijun as Chief Financial Officer, Effective July 31, 2026	CI
31/07	Medtide Inc. Announces Management Changes, Effective July 31, 2026	CI
31/07	Medtide Inc. Announces Change of Principal Place of Business in Hong Kong	CI
31/07	Medtide Inc. Provides Group Earnings Guidance for the Six Months Ended Year Ended June 30, 2026	CI
30/06	95,524,875 H Shares of Medtide Inc. are subject to a Lock-Up Agreement Ending on 29-JUN-2026.	CI
18/06	Medtide Inc. Announces Abolishment of the Supervisory Committee	CI
31/03	Medtide Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
09/03	Medtide Completes Hong Kong-Listed Share Full Circulation	MT

Medtide Inc. Share Price

Stocks

3880

CNE100006S86

Biotechnology & Medical Research

Valuation: Medtide Inc.

Chart: Medtide Inc.

Latest news: Medtide Inc.

Press Releases: Medtide Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Medtide Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Analysts' Consensus

Net sales - Rate of surprise

1 day	-1.23%
1 week	-3.95%
Current month	+0.68%
1 month	-8.86%
3 months	-3.85%
6 months	-12.75%
Current year	-36.91%

1 week	18.03	20.1
1 month	18.03	21.48
Current year	17.64	30.46
1 year	17.64	31.98
3 years	17.64	41.72
5 years	17.64	41.72
10 years	17.64	41.72

Manager	Title	Age	Since
Qi Xu CEO	Chief Executive Officer	58	11/06/2020
Li Jun Ding DFI	Director of Finance/CFO	50	31/07/2026
Wei Qun Xu DFI	Director of Finance/CFO	53	01/10/2020

Director	Title	Age	Since
Qi Xu CHM	Chairman	58	11/06/2020
Xiang Li Li BRD	Director/Board Member	51	27/01/2022
Xiang Li BRD	Director/Board Member	63	27/01/2022

Date	Insider	Type	Main position	Quantity	% Market Cap.
09/03/26	Qi Xu	Other	Chief Executive Officer	6,82,01,112	48.0967%
09/03/26	Xiang Li Li	Other	Director	6,82,01,112	48.0967%
09/03/26	Qi Xu	Other	Chief Executive Officer	6,82,01,112	48.0967%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
MEDTIDE INC.	-1.23%	-3.95%	-37.16%	-	35Cr
WUXI APPTEC CO., LTD.	-2.43%	-4.38%	+40.32%	+55.64%	6.22TCr
LONZA GROUP AG	+0.62%	+2.58%	+20.96%	+98.18%	5.53TCr
ARGENX SE	+0.61%	+0.77%	+11.13%	+69.42%	5.49TCr
IQVIA HOLDINGS INC.	+1.61%	-3.30%	+22.77%	+33.16%	4.26TCr
BEONE MEDICINES AG	-1.74%	-3.02%	+13.83%	+93.17%	4.11TCr
REVOLUTION MEDICINES, INC.	+3.22%	+4.30%	+227.37%	+776.49%	4.03TCr
GENMAB A/S	+0.57%	+24.09%	+99.46%	+84.11%	3.31TCr
CELLTRION, INC.	-1.09%	+0.69%	+14.20%	+45.26%	3.26TCr
INSMED INCORPORATED	-4.46%	+9.98%	-43.92%	+320.28%	2.4TCr
Average	-0.43%	+2.93%	+36.90%	+175.08%	3.86TCr
Weighted average by Cap.	-0.21%	+2.11%	+45.74%	+158.50%

	2026 *	2027 *
Net sales	60Cr 70Cr 8.97Cr 8.01Cr 7.36Cr 6.69Cr 13Cr 849.7Cr 13Cr 88Cr 35Cr 448.47Cr 34Cr 33Cr 1.42TCr	74Cr 87Cr 11Cr 9.94Cr 9.13Cr 8.29Cr 16Cr 1.05TCr 16Cr 108.96Cr 44Cr 556.11Cr 42Cr 41Cr 1.76TCr
Net income	-	-
Net Debt	-58Cr -68Cr -8.68Cr -7.75Cr -7.12Cr -6.47Cr -12Cr -821.82Cr -12Cr -85Cr -34Cr -433.76Cr -33Cr -32Cr -1.37TCr	-65Cr -76Cr -9.73Cr -8.69Cr -7.98Cr -7.25Cr -14Cr -921.24Cr -14Cr -95Cr -38Cr -486.23Cr -37Cr -36Cr -1.54TCr